BioLineRx shares are trading higher after the FDA approved the company's Aphexda plus filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection, subsequent autologous transplantation in multiple myeloma patients
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved BioLineRx's Aphexda plus filgrastim for use in mobilizing hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in multiple myeloma patients. This has led to an increase in the company's share price.
September 11, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioLineRx's shares are trading higher following the FDA's approval of Aphexda plus filgrastim. This approval could potentially increase the company's revenues and market share.
The FDA's approval of BioLineRx's Aphexda plus filgrastim is a significant milestone for the company. This approval not only validates the company's product but also opens up a new revenue stream. As a result, investors are likely to view this development positively, leading to an increase in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100